Results: Data were available on 54 284 subjects (52% female). During follow-up (median 21 years), 283 women and 110 men developed RA. The median (IQR) time to onset of RA was 7 (4-11) years. The adjusted hazard ratio's (HR) for developing RA are presented in Table 1 . Restricted cubic spline analysis of body fat percentage displayed a positive slope in women (Image). There was no linear association between amount of fat and incidence of RA among men. Conclusions: Overweight and obesity, defined by BMI, abdominal obesity and higher body fat percentage, especially above 30%, were in women associated with a higher risk for the development of RA. In men the associations were not consistent. Background: There is emerging evidence suggesting that offspring born to patients with rheumatic diseases has higher risk of neuropsychiatric diseases. Previous data from Quebec showed children born to women with SLE have an increased risk of autism spectrum disorder (ASD) but data regarding risk of ASD in offspring of mothers with systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA) mothers have not been reported in other population. Objectives: We aimed to examine whether offspring of mothers with SLE and RA in Taiwan has a higher risk of developing ASD using data from a linkage between National Health Insurance (NHI) database and National Birth Registry in Taiwan. Methods: We established a birth cohort of all live-births between 2001 and 2012 in Taiwan established using the National Health Insurance database and the National Birth Registry. Children born to mothers with SLE or RA were identified and matched up to 8 controls by maternal age, 1-minute Apgar score, 5-minute Apgar score, mode of delivery, sex of child, gestational age, birth weight, socioeconomic status (place of residence, income level, occupation). A marginal Cox proportional hazard models were used to estimate the relative risk (RR; 95% confidence interval [CI]) for ASD in newborns with affected mothers. Results: Of 1,893,244 newborns, 0.08% (n=1,594) were born to mothers with SLE (mean age 30.43±4.37 years old) and 0.04% (n=673) were born to mothers with RA (31.97±4.51 years old). Overall, 5 of 673 (0.74%) RA offspring developed ASD, 7 of 1594 (0.44%) SLE offspring developed ASD and 10,631 of 1,893,244 (0.56%) all infants developed ASD. 
Scleroderma, myositis and related ethology OP0081 PAN-PPAR AGONIST IVA337 IS EFFECTIVE IN THE PREVENTION OF EXPERIMENTAL LUNG FIBROSIS AND PULMONARY HYPERTENSION
Objectives: Our objective was to evaluate the antifibrotic effects of IVA337 in preclinical mouse models of pulmonary fibrosis and related pulmonary hypertension (PH). Methods: IVA337 has been evaluated in the mouse model of bleomycin-induced pulmonary fibrosis and in Fra-2 transgenic mice, this latter being characterized by non-specific interstitial pneumonia and severe vascular remodeling of pulmonary arteries leading to PH. Mice received 2 doses of IVA337 (30 mg/kg or 100 mg/kg) or vehicle administered by daily oral gavage up to 4 weeks. Results: Both 30 mg/kg and 100 mg/kg doses of IVA337 were well tolerated in all mouse models. IVA337 demonstrated at a dose of 100 mg/kg a marked protection from the development of lung fibrosis induced by bleomycin compared to mice receiving 30 mg/kg of IVA337 or vehicle. Indeed, IVA337 (100 mg/kg) strongly reduced by 61% and 28% tissue density on histological measurements and total lung hydroxyproline concentrations, respectively, as compared to vehicle. IVA337 at 100 mg/kg also significantly decreased col1, col3 and fibronectin in lesional lungs. Similarly, Fra-2 transgenic mice treated with 100 mg/kg of IVA337 displayed reduced lung density (20% vs. vehicle) and significant increase of functional residual capacity (30% vs. vehicle) when assessed by chest micro-CT imaging. These results were emphasized by a 50% reduction of the Ascroft fibrosis score ( Figure 1A) and by a 48% reduction of hydroxyproline concentrations upon IVA337 (100 mg/kg) compared to vehicle treated mice. Successful targeting of the TGF-b signaling axis was observed in both mouse models upon treatment with 100 mg/kg of IVA337. 100 mg/kg IVA337 also significantly reduced T cell and B cell infiltration in lesional lungs of Fra-2 transgenic mice. Regarding vessel remodeling and related pulmonary hypertension, treatment with 100 mg/kg of IVA337 led to a substantial attenuation of right ventricular systolic pressure and right ventricular hypertrophy compared to mice receiving the vehicle ( Figure 1B and 1C) . Furthermore, IVA337 given at 100 mg/kg markedly reduced medial wall thickness ( Figure 1D ) and the number of muscularized distal pulmonary arteries. In vitro in primary human lung fibroblasts, IVA337 inhibited in a dose-dependent manner TGFβ-mediated fibroblasts to myofibroblasts transition and PDGFmediated proliferation. 
